AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1492231 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 3890909 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (continuous infusion increasing from 0.01 mg kg‐1 min‐1 to 0.05 mg kg‐1 min‐1 over 50 min)
Number of subjects: 14
Study 3890909 — intervention group
Group type: COMPARATOR
Intervention: Saline (equivalent volume to etomidate)
Number of subjects: 14
Study 31912491 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) for 6 weeks as adjunctive treatment to supervised exercise.
Number of subjects: 62
Study 31912491 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) for 6 weeks.
Number of subjects: 62
Study 31912491 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise programme only.
Number of subjects: 62
Study 31046522 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydration (EU)
Number of subjects: 10
Study 31046522 — intervention group
Group type: COMPARATOR
Intervention: Hypohydration (HH)
Number of subjects: 10
Study 28699973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group focusing on lifestyle changes, physical activities, and nutritional education, with activities occurring monthly in the school's multimedia room or sports court.
Number of subjects: 0
Study 28699973 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving usual recommendations by the school.
Number of subjects: 0
Study 27244537 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 courses of S-1 plus cisplatin (SC)
Number of subjects: 83
Study 27244537 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 courses of S-1 plus cisplatin (SC)
Number of subjects: 83
Study 27244537 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 courses of paclitaxel plus cisplatin (PC)
Number of subjects: 83
Study 27244537 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 courses of paclitaxel plus cisplatin (PC)
Number of subjects: 83
Study 24835418 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap debridement (OFD) in endodontically treated teeth with chlorhexidine (CHX) placed in the coronal space (test)
Number of subjects: 31
Study 24835418 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD) in endodontically treated teeth (control)
Number of subjects: 31
Study 23011712 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg; maximum dose, 20 mg)
Number of subjects: 314
Study 23011712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 314
Study 23011712 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 314
Study 23011712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 20212252 — intervention group
Group type: COMPARATOR
Intervention: Continuous 6-mercaptopurine (6-MP) and weekly methotrexate (MTX)
Number of subjects: 544
Study 20212252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent 6-mercaptopurine (100 mg/m(2)/d for 10 days, with 11 days resting) and MTX (200 mg/m(2) every 3 weeks)
Number of subjects: 544
Study 20212252 — intervention group
Group type: COMPARATOR
Intervention: Intermittent regimen (group 2) vs Continuous regimen (group 1) in boys
Number of subjects: 544
Study 20212252 — intervention group
Group type: COMPARATOR
Intervention: Intermittent regimen (group 2) vs Continuous regimen (group 1) in girls
Number of subjects: 544
Study 20212252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent 6-mercaptopurine and MTX
Number of subjects: 544
Study 17621202 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaved group (371 patients)
Number of subjects: 789
Study 17621202 — intervention group
Group type: COMPARATOR
Intervention: Unshaved group (418 patients)
Number of subjects: 789
Study 16236917 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported arm exercise training plus general physiotherapy (gPT)
Number of subjects: 66
Study 16236917 — intervention group
Group type: COMPARATOR
Intervention: General physiotherapy (gPT) alone
Number of subjects: 66
Study 11869857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 108
Study 11869857 — intervention group
Group type: EXPERIMENTAL
Intervention: Model prediction based on NYHA and LAT area
Number of subjects: 108
Study 11869857 — intervention group
Group type: EXPERIMENTAL
Intervention: Model performance in validating sample
Number of subjects: 108
Study 10609427 — intervention group
Group type: EXPERIMENTAL
Intervention: Offset control over gas inhalation
Number of subjects: 30
Study 10609427 — intervention group
Group type: COMPARATOR
Intervention: No offset control over gas inhalation
Number of subjects: 30
Study 10609427 — intervention group
Group type: EXPERIMENTAL
Intervention: Offset control in Phase I
Number of subjects: 30
Study 10609427 — intervention group
Group type: COMPARATOR
Intervention: No offset control in Phase I
Number of subjects: 30
Study 7538925 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal ALT
Number of subjects: 200
Study 7538925 — intervention group
Group type: COMPARATOR
Intervention: Normal ALT
Number of subjects: 200
Study 7538925 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal LFTs (White Caucasians)
Number of subjects: 200
Study 7538925 — intervention group
Group type: COMPARATOR
Intervention: Normal LFTs (White Caucasians)
Number of subjects: 200
Study 7538925 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal LFTs (Asians)
Number of subjects: 200
Study 7538925 — intervention group
Group type: COMPARATOR
Intervention: Normal LFTs (Asians)
Number of subjects: 200
Study 2317427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 15 micrograms kg‐1
Number of subjects: 30
Study 2317427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 micrograms kg‐1
Number of subjects: 30
Study 2317427 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study 7426219 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg kg‐1 i.v. (group I)
Number of subjects: 80
Study 7426219 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallamine 0.3 mg kg‐1 i.v. (group II)
Number of subjects: 80
Study 7426219 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg kg‐1 i.m. and gallamine 0.3 mg kg‐1 i.v. (group III)
Number of subjects: 80
Study 7426219 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg kg‐1 i.v. and gallamine 0.3 mg kg‐1 i.v. (group IV)
Number of subjects: 80
Study 31373921 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental variable (IV) estimators
Number of subjects: 0
Study 31373921 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ages at study inclusion
Number of subjects: 0
Study 31373921 — intervention group
Group type: EXPERIMENTAL
Intervention: One-sample vs two-sample estimation
Number of subjects: 0
Study 28112773 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training plus calorie‐restricted diet (SDG)
Number of subjects: 51
Study 28112773 — intervention group
Group type: COMPARATOR
Intervention: Diet group (DG)
Number of subjects: 51
Study 26435849 — intervention group
Group type: EXPERIMENTAL
Intervention: Litramine (3 g/day)
Number of subjects: 0
Study 26435849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23768279 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral manipulation (VM) added to standard physiotherapy treatment regimen.
Number of subjects: 0
Study 23768279 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy treatment regimen (manual therapy, specific exercise, functional exercise prescription).
Number of subjects: 0
Study 21417617 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release liquid form of codeine (69.7 mg every 12 h)
Number of subjects: 0
Study 21417617 — intervention group
Group type: COMPARATOR
Intervention: Codeine in solution (23.2 mg every 4 h)
Number of subjects: 0
Study 19515791 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) for 2 weeks
Number of subjects: 54
Study 19515791 — intervention group
Group type: COMPARATOR
Intervention: Obese group (including T2DM)
Number of subjects: 54
Study 19515791 — intervention group
Group type: COMPARATOR
Intervention: T2DM group
Number of subjects: 54
Study 19515791 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of serum MIC‐1 levels
Number of subjects: 54
Study 18393643 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL prilocaine infiltration
Number of subjects: 121
Study 18393643 — intervention group
Group type: COMPARATOR
Intervention: 20 mL prilocaine infiltration
Number of subjects: 121
Study 16239807 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave therapy
Number of subjects: 49
Study 16239807 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 49
Study 12172339 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine 8 to 10 mg/day
Number of subjects: 381
Study 12172339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 to 40 mg/day
Number of subjects: 381
Study 12172339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 10692976 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) and 1000 mg calcium per day (n = 10)
Number of subjects: 34
Study 10692976 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg calcium per day (n = 14)
Number of subjects: 34
Study 10692976 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group, n = 10)
Number of subjects: 34
Study 7476595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantothenic acid replacement therapy, dosage and duration not specified
Number of subjects: 0
Study 2337215 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 20 mg by intramuscular injection 6 hourly for 24 hours
Number of subjects: 84
Study 2337215 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg 12-hourly and placebo injections at 6 and 18 hours
Number of subjects: 84
Study 2337215 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nefopam and diclofenac
Number of subjects: 84
Study 6996897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg intravenously)
Number of subjects: 6
Study 6996897 — intervention group
Group type: COMPARATOR
Intervention: Histamine (0.13 microgram/kg/min for 20 min)
Number of subjects: 6
Study 6996897 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine with Cimetidine pretreatment
Number of subjects: 6
Study 6996897 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine and Cimetidine
Number of subjects: 6
Study 30661768 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine
Number of subjects: 150
Study 30661768 — intervention group
Group type: COMPARATOR
Intervention: Control (no protamine)
Number of subjects: 150
Study 26873789 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean-seafood diet
Number of subjects: 20
Study 26873789 — intervention group
Group type: COMPARATOR
Intervention: Nonseafood diet
Number of subjects: 20
Study 24898987 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS)
Number of subjects: 51
Study 24898987 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 51
Study 22305043 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen availability in locker rooms and golf bags
Number of subjects: 83
Study 22305043 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sunscreen availability)
Number of subjects: 83
Study 20128823 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 31
Study 20128823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 18832244 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc once daily
Number of subjects: 1049
Study 18832244 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc twice daily
Number of subjects: 1049
Study 18832244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1049
Study 16837136 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheeting (Cica-Care) applied 24h per day for 6 months
Number of subjects: 45
Study 16837136 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (daily massage for 15 min)
Number of subjects: 45
Study 16837136 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheeting (Cica-Care)
Number of subjects: 45
Study 12847427 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational brochure and video (CALM approach)
Number of subjects: 216
Study 12847427 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 216
Study 10668125 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved sleep hygiene instructions (Group A)
Number of subjects: 70
Study 10668125 — intervention group
Group type: COMPARATOR
Intervention: No instructions on improving sleep hygiene (Group B)
Number of subjects: 70
Study 7562017 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day antibiotic prophylaxis (clindamycin and cefonicid)
Number of subjects: 126
Study 7562017 — intervention group
Group type: COMPARATOR
Intervention: Three-day antibiotic prophylaxis (clindamycin and cefonicid)
Number of subjects: 126
Study 1935632 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2‐containing water (1400 mg CO2/kg H2O) at 34 degrees C for 20 minutes
Number of subjects: 16
Study 1935632 — intervention group
Group type: COMPARATOR
Intervention: Fresh water at 34 degrees C for 20 minutes
Number of subjects: 16
Study 6988950 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg) and tinidazole (2 g)
Number of subjects: 307
Study 31469512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoisochromatic (PIC) test
Number of subjects: 71
Study 31469512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mollon‐Reffin minimalist (MRM) test
Number of subjects: 71
Study 31469512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cambridge Colour Test (CCT)
Number of subjects: 71
Study 31469512 — intervention group
Group type: COMPARATOR
Intervention: Age effect on CCT
Number of subjects: 71
Study 31164362 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting intervention
Number of subjects: 52
Study 31164362 — intervention group
Group type: COMPARATOR
Intervention: Usual care planning (Control)
Number of subjects: 52
Study 28270129 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intake approach facilitated by Routine Outcome Monitoring (ROM), peer support, and training of clinicians
Number of subjects: 176
Study 28270129 — intervention group
Group type: COMPARATOR
Intervention: Intake as usual
Number of subjects: 176
Study 28270129 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intake approach
Number of subjects: 176
Study 25933795 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (VAR) 1 mg BID
Number of subjects: 120
Study 25933795 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 25 mg QD
Number of subjects: 120
Study 25933795 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of VAR + NTX
Number of subjects: 120
Study 25933795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23763614 — intervention group
Group type: EXPERIMENTAL
Intervention: VeinViewer®
Number of subjects: 1913
Study 23763614 — intervention group
Group type: EXPERIMENTAL
Intervention: AccuVein® AV300
Number of subjects: 1913
Study 23763614 — intervention group
Group type: EXPERIMENTAL
Intervention: VascuLuminator Vision®
Number of subjects: 1913
Study 23763614 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1913
Study 21819569 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth and telecare
Number of subjects: 0
Study 21819569 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19548064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronate (HA) injections
Number of subjects: 720
Study 17109866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/day)
Number of subjects: 52
Study 17109866 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (40 mg/day)
Number of subjects: 52
Study 15118606 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 0
Study 15118606 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study 11693870 — intervention group
Group type: EXPERIMENTAL
Intervention: N,N-diethyl-M-toluamide (DEET) 1.7 g/day
Number of subjects: 897
Study 9051820 — intervention group
Group type: COMPARATOR
Intervention: Defibrillation without pulse checks
Number of subjects: 20
Study 9051820 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation with pulse checks by an assistant
Number of subjects: 20
Study 9051820 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation with pulse checks by the participant
Number of subjects: 20
Study 8189337 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-informed malingerer group
Number of subjects: 60
Study 8189337 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 8189337 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 60
Study 3300157 — intervention group
Group type: EXPERIMENTAL
Intervention: oxandrolone, 0.125 mg/kg/day (Group 2)
Number of subjects: 70
Study 3300157 — intervention group
Group type: EXPERIMENTAL
Intervention: somatrem, 0.125 mg/kg 3 times/week (Group 3)
Number of subjects: 70
Study 3300157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of somatrem and oxandrolone (Group 4)
Number of subjects: 70
Study 3300157 — intervention group
Group type: EXPERIMENTAL
Intervention: somatrem, 0.125 mg/kg 3 times/week and oxandrolone, 0.0625 mg/kg/day (after 12-20 months for Groups 1, 2, and 4)
Number of subjects: 70
Study 3300157 — intervention group
Group type: EXPERIMENTAL
Intervention: somatrem and combination groups
Number of subjects: 70
Study 3300157 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 70
Study 3300157 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 70
Study 31800354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 300 mg/day (range 100-600 mg)
Number of subjects: 21
Study 31800354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC) 10 mg/day (range 5-30 mg)
Number of subjects: 21
Study 31800354 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Symptom Distress Scores (TSDS) measured using the Edmonton Symptom Assessment Scale
Number of subjects: 21
Study 31800354 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse Events (AEs)
Number of subjects: 21
Study 31519516 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal in-bore MRI targeted biopsy (MRI-TB)
Number of subjects: 234
Study 31519516 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal MRI-transrectal ultrasound fusion targeted biopsy (FUS-TB)
Number of subjects: 234
Study 31519516 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal cognitive TRUS targeted biopsy (COG-TB)
Number of subjects: 234
Study 31519516 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal approaches (MRI-TB + COG-TB)
Number of subjects: 234
Study 31519516 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy
Number of subjects: 234
Study 28376972 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-led workshop
Number of subjects: 32
Study 28376972 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led workshop
Number of subjects: 32
Study 28376972 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study 25953805 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for piperacillin, adjusted to achieve 100% fT>MIC
Number of subjects: 32
Study 25953805 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for piperacillin, adjusted to achieve 50% fT>MIC
Number of subjects: 32
Study 25953805 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for piperacillin, baseline to after third TDM
Number of subjects: 32
Study 25953805 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TDM)
Number of subjects: 32
Study 25953805 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of fever and days to recovery from neutropenia
Number of subjects: 32
Study 22986930 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose retinol supplement (25,000 IU retinyl palmitate/day) for up to 16 years
Number of subjects: 2322
Study 22986930 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 2322
Study 21839850 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 2 μg
Number of subjects: 36
Study 21839850 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg
Number of subjects: 36
Study 21839850 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg
Number of subjects: 36
Study 21839850 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 20 μg
Number of subjects: 36
Study 21839850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21839850 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol (all doses)
Number of subjects: 36
Study 21839850 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol (40 μg)
Number of subjects: 36
Study 18068876 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate vaccine (recombinant protein HIV-1 gp160MN/LAI with or without DC-Chol adjuvant) administered by the nasal or vaginal route
Number of subjects: 34
Study 16858354 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 70
Study 16858354 — intervention group
Group type: COMPARATOR
Intervention: No statin (control)
Number of subjects: 70
Study 15199384 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol ester-enriched (PSE) spread (20 g/day)
Number of subjects: 57
Study 11270916 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day (increased to 40 mg/day after 2 weeks)
Number of subjects: 31
Study 11270916 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg/day (increased to 150 mg/day after 2 weeks)
Number of subjects: 31
Study 11270916 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lithium and antidepressant therapy (both paroxetine and amitriptyline)
Number of subjects: 31